TABLE 2.
Lung CFU counts assessed during treatment and proportions of mice relapsing after treatment completion
| Treatment | Log10 CFU (mean ± SD)a |
% of mice relapsing (no. relapsing/total no.) at week 4(+12) | |||
|---|---|---|---|---|---|
| Day −13 | Day 0 | Week 2 | Week 4 | ||
| None | 3.98 ± 0.09 | 7.95 ± 0.25 | 9.57 ± 0.08 | ||
| Verapamil | 9.62 ± 0.48 | ||||
| Bedaquiline at 12.5 mg/kg | 4.02 ± 0.18 | ||||
| Bedaquiline at 12.5 mg/kg plus verapamil | 3.29 ± 0.73 | ||||
| Bedaquiline at 18 mg/kg | 3.52 ± 0.33 | ||||
| Clofazimine at 12.5 mg/kg | 5.32 ± 0.18 | ||||
| Clofazimine at 12.5 mg/kg plus verapamil | 5.42 ± 0.16 | ||||
| BCZ | 0.84 ± 0.28 | 60 (6/10) | |||
| BCZV | 0.63 ± 0.39 | 27 (4/15) | |||
a
Time points are shown as days (day −13 or day 0) or weeks (week 2 or week 4) of treatment. Week 4(+12) indicates that the mice were held for 12 additional weeks after completing 4 weeks of treatment.